Description: Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; Percepta Nasal Swab Test for lung cancer diagnosis; and Envisia Genomic Classifier for diagnosing interstitial lung disease, including idiopathic pulmonary fibrosis. It is also developing Envisia Classifier, the nCounter analysis system; and LymphMark for lymphoma subtyping test. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
Home Page: www.veracyte.com
6000 Shoreline Court
South San Francisco,
CA
94080
United States
Phone:
650 243 6300
Officers
| Name | Title |
|---|---|
| Mr. Marc A. Stapley | CEO & Director |
| Ms. Rebecca Chambers | Executive VP & CFO |
| Dr. Phillip G. Febbo M.D. | Chief Scientific & Medical Officer |
| Ms. Annie McGuire | Executive VP, General Counsel & Chief People Officer |
| Dr. John Leite Ph.D. | Chief Commercial Officer |
| Dr. Keith Gligorich Ph.D. | Senior Vice President of Global Operations |
| Mr. Jonathan Wygant | VP & Chief Accounting Officer |
| Mr. Steven French | Senior VP & Chief Information Officer |
| Ms. Karen Possemato | Senior Vice President of Corporate Marketing, Communications & Commercial Operations |
| Mr. Robert Brainin | Executive VP & Chief Business Officer |
Exchange: F
Country: DE : Germany
Currency: Euro (€)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 45.2489 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 2.8181 |
| Price-to-Sales TTM: | 7.4257 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 815 |